OPTN/SRTR 2023 Annual Data Report: Pancreas

Raja Kandaswamy^1,2, Peter G. Stock^1,3, Jonathan M. Miller^1,4, Dzhuliyana Handarova⁵, Ajay K. Israni^1,6, Jon J. Snyder^1,4,7

¹Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN

²Department of Surgery, University of Minnesota, Minneapolis, MN

³Department of Surgery, University of California San Francisco, San Francisco, CA

⁴Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, MN

⁵Organ Procurement and Transplantation Network, United Network for Organ Sharing, Richmond, VA

⁶Department of Medicine, University of Texas Medical Branch, Galveston, TX

⁷Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

Abstract

The overall number of pancreas transplants in the United States remained relatively unchanged in 2023 at 915 transplants, compared with 918 transplants in 2022. The number of pancreas-after-kidney transplants continued to decline and reached the lowest level in the past decade: 36 transplants in 2023. The proportion of pancreas recipients with type 2 diabetes increased to 25.4% in 2023 from 22.5% in 2022, comparable to the proportion of candidates with type 2 diabetes on the waiting list increasing to 25.2% in 2023 compared with 23.4% in 2022. The number of adult additions to the pancreas waiting list increased in 2023 to 1,876 compared with 1,736 in 2022. The proportion of candidates on the waiting list who are older, obese, or have type 2 diabetes has been increasing. The number of pancreas donors decreased in 2023 compared with 2022; however, the nonuse rate also decreased during the same period. The distribution of volume across transplant centers was relatively unchanged in 2023, with only 5% of centers performing more than 30 transplants a year. Outcomes of pancreas transplants were relatively stable from 2020 to 2022, with 1-year pancreas graft survival rates in adults of 90.8% in simultaneous pancreas-kidney transplant, 87.5% in pancreas transplant alone, and 84.4% in pancreas-after-kidney transplant for transplants performed in 2022. Kidney 1-year graft survival in simultaneous pancreas-kidney transplant was excellent at 96.2% for transplants in 2022. Keywords: Pancreas transplant, transplant outcomes, waitlist outcomes

1 Introduction

As part of its effort to develop a continuous distribution system for pancreas allocation in the United States since the previous Annual Data Report, the Organ Procurement and Transplantation Network (OPTN) Board of Directors has asked the kidney and pancreas committees to prioritize the utilization of organs in the new allocation system. Consequently, the Pancreas Transplantation Committee has submitted a request to the Scientific Registry of Transplant Recipients (SRTR) to update the Organ Allocation Simulation (OASim) software model to determine whether simulation can answer questions related to organ nonuse. At the time of this writing, this work is ongoing at SRTR.

The Pancreas Committee is also working on developing medical urgency criteria for pancreas candidates. Subject matter experts in the area have appeared before the Committee to help with specific criteria for hypoglycemia unawareness being included as an attribute for medical urgency. In addition, it was proposed that a Pancreas Review Board (yet to be formed) will serve as the determining body for medical urgency of pancreas candidates.

Another agenda item before the Pancreas Committee is implementation of measures to improve efficiency in the procurement and utilization of pancreata. The committee intends to release a guidance document to include best practices and guidance on procurement of pancreata.

To summarize, most of the initiatives in pancreas transplant allocation and policy over the past year were aimed at improving utilization while developing a system of continuous distribution.

2 Waiting List

The number of new adult candidates added to the waiting list in 2023 increased for simultaneous pancreas-kidney (SPK) transplant (1,585 in 2023 versus 1,485 in 2022) and pancreas-after-kidney (PAK) transplant (111 in 2023 versus 71 in 2022), whereas it remained unchanged in pancreas transplant alone (PTA) (180 in both 2022 and 2023) (Figure PA 1). Of note, the number of new listings in SPK is the highest over the past decade. This may suggest a delayed postpandemic recovery in additions to the waiting list for pancreas transplant and should be monitored over the next couple of years.

Increases were seen in prevalent adult listings for SPK (3,549 in 2023 versus 3,339 in 2022), PAK (370 in 2023 versus 355 in 2022), and PTA (564 in 2023 versus 541 in 2022) (Figure PA 2).

The age distribution of adult candidates on the waiting list was largely unchanged in 2023 compared with 2022. However, as noted in prior reports, the proportion of older candidates (age 55 years or older) has increased over the past decade: 14.8% in 2023 compared with 12.1% in 2012 (Figure PA 3). This is consistent with an increasing proportion of candidates with type 2 diabetes on the waiting list.

The sex distribution of adult candidates on the waiting list was unchanged from prior years, with an overall male preponderance in 2023: 53.7% male and 46.3% female (Figure PA 4). Of note, there was a female preponderance on the waiting list for PTA (53.2% female and 46.8% male at the end of 2023) (Table PA 1), as has been the case historically.

Over the past decade, there has been an increase in the proportion of adult candidates on the waiting list who were Asian, Black, and Hispanic, with a corresponding decrease in candidates who were White. In 2023, 46.5% were White, 29.2% were Black, 17.5% were Hispanic, and 4.8% were Asian, compared with 2012, when the percentages were 67.4%, 18.5%, 11.2%, and 1.8%, respectively. Again, this is likely due to the impact of type 2 diabetes on the waiting list (Figure PA 5).

The proportion of adult candidates with type 2 diabetes on the waiting list has continued to increase steadily over the past decade since the pancreas allocation system was implemented in 2014. There has been a 204.5% increase in the type 2 diabetes diagnosis category: 25.2% in 2023 compared with 8.3% in 2012. Correspondingly, the type 1 diabetes category has had a 19.6% decline: 66.9% in 2023 compared with 83.3% in 2012 (Figure PA 6). With the increasing proportion of candidates with type 2 diabetes on the list, there has been a concurrent increase in the proportion of candidates who are obese. In 2023, 23.7% of candidates had a body mass index (BMI) of 30 or greater, compared with 18.7% in 2012 (Figure PA 8).

The distribution of candidates by waiting time has not appreciably changed since 2020, with about half of adult pancreas transplant candidates (50.4%) in 2023 having waiting times of 1 year or longer (Figure PA 7). The distribution of adult candidates by blood type has not changed dramatically year over year; however, over the past decade, there has been a trend toward a higher proportion of candidates with blood type B (16.4% in 2023 versus 13.1% in 2012) with a corresponding decrease in candidates with blood type O (47.6% in 2023 versus 50.2% in 2012) (Figure PA 9).

When looking at the waiting list by intended transplant category for adults, SPK continued to increasingly dominate (79.2% in 2023) followed by PTA (12.6%) and PAK (8.3%). Of note, the PAK listings have decreased by about 50% over the past decade (Figure PA 10).

The proportion of retransplant candidates has been steadily decreasing over the past decade (6.3% in 2023 versus 15.4% in 2012) (Figure PA 11). This is partly attributable to the decrease in PAK listings (Figure PA 2), where retransplant listings are the highest (22.2%) (Table PA 3).

While new listings have increased in the past 5 years, there has not been an increase in transplant rates. Transplant rates for adults decreased to 35.4 transplants per 100 patient-years in 2023, from 44.8 in 2019 (Figure PA 12). This may be due to centers being more selective with donors and avoidance of risk. There were no clear trends in transplant rates by diabetes type (Figure PA 13). By blood type, there was a spike in the transplant rate for blood type AB in 2023 to 55.9 transplants per 100 patient years. However, this is a very small proportion of the overall population and is likely not significant (Figure PA 14). The decrease in transplant rates has been across all pancreas transplant categories (SPK, PAK, and PTA) over the past 5 years (Figure PA 15).

For outcome on the waiting list, 46.3% of adult SPK candidates received a deceased donor transplant at 1 year (Figure PA 18), compared with 35.6% of PTA candidates (Figure PA 17) and only 22.6% of PAK candidates (Figure PA 16). This disparity extended to 3 years, when 60.6% of SPK candidates had received a deceased donor transplant compared with 45.9% of PTA candidates and 34% of PAK candidates. The long waiting times for solitary pancreas transplant, especially PAK, is concerning and may have an unintended consequence of making PAK that starts with a living donor kidney a less attractive option for candidates who have a living donor.

Waitlist mortality among adults has shown a favorable trend over the past decade: 4.6 deaths per 100 patient-years in 2023 compared with 5.6 in 2014 (Figure PA 19). Mortality spiked at the beginning of the COVID-19 pandemic to 6.2 deaths per 100 patient-years in 2020 but has since decreased in the postpandemic era. This may be due to a combination of better list management and selective listing practices. Mortality for candidates aged 55 years or older declined sharply to 4.9 deaths per 100 patient-years in 2023, compared with 8.9 in 2022, but this is likely due to the small numbers in this age group and not significant (Figure PA 20). There were no notable trends in mortality by race and ethnicity (Figure PA 21). Differences by sex were notable in that the waitlist mortality for female candidates has been consistently decreasing since the COVID-19 pandemic began in 2020, whereas the trend is not as consistent for male candidates (Figure PA 22). Since 2020, SPK candidates have shown a consistent decrease in waitlist mortality (5.3 deaths per 100 patient-years in 2023 versus 7.1 in 2020), while the trends for PAK and PTA candidates were less consistent, presumably due to small numbers (Figure PA 23). Pretransplant mortality rates by donation service area show wide variability (range in 2023: 0-21.2 deaths per 100 patient-years), but this is probably skewed by small numbers in some donation service areas (Figure PA 24).

Deaths within 6 months after removal from the waiting list (for reasons other than transplant) among adult candidates declined substantially from 8.0% in 2022 to 3.4% in 2023 (Figure PA 25)—the lowest level in a decade after steadily increasing from 2019 to 2022 (presumably affected by COVID-19). The decrease in deaths within 6 months of removal from the waiting list was uniform across all age groups (Figure PA 26) and across all transplant types, except PAK where the numbers were small (Figure PA 27).

Regarding access to a transplant center, note that only 4.6% of SPK candidates in 2023 lived 250 miles or farther from their transplant center whereas 17.4% of PTA candidates did (Table PA 1). Solitary pancreas transplants are performed at selected centers, and access may involve traveling long distances.

3 Donations

The number of deceased donors whose pancreas was recovered for transplant decreased to 1,194 in 2023 compared with 1,286 in 2022 (Figure PA 28). However, the number of pancreas transplants did not change appreciably during that time (915 in 2023 and 918 in 2022) (Figure PA 41), suggesting that the nonuse rate for pancreata decreased in 2023. There is a continuing preference for using pancreata from young donors, with 70.9% of donors in 2023 under age 30 (Figure PA 29). Male preponderance among pancreas donors continued in 2023: 69.9% male and 30.1% female (Figure PA 30). White donors continued to constitute the majority in 2023, at 60.9% (Figure PA 31), while White individuals received 42.5% of the transplants (Figure PA 45). The proportion of Black (20.7% in 2023) and Hispanic (16% in 2023) donors remained largely unchanged in the past few years. Donors of lower weight (<20 kg, usually pediatric) also remained uncommon, at 1.3% of donors in 2023 (Figure PA 33). Donors with higher BMI (30 or greater) or with lower BMI (<18.5) remained less common in 2023: 7.9% and 7.8%, respectively (Figure PA 32).

Head trauma continued to be the leading cause of death among donors and had an uptick to 50.7% in 2023 (versus 47.0% in 2022). Meanwhile, anoxia, which has been steadily increasing for over a decade with increasing drug-related deaths, showed a small decrease as a cause of donor death for the first time in many years. It is to be hoped that this is the start of a positive trend of decreasing drug-related mortality in the United States (Figure PA 34). Regarding pancreata recovered with the intent for transplant, the nonuse rate was 23.4% in 2023 compared with 28.7% in 2022. This was a substantial decrease in nonuse after the rate had been increasing since 2020 (Figure PA 35) and one that it is hoped will continue. Nonuse rates decreased for younger donors (age <40 years), whereas they increased among older donors (40 years or older), reinforcing the previously noted preference for pancreata from younger donors (Figure PA 36). Of interest, the decrease in nonuse in 2023 was only observed for male donors (21.4% in 2023 versus 29.2% in 2022) while the nonuse rate for female donors was unchanged (27.9% in 2023 versus 27.6% in 2022) (Figure PA 37). Nonuse rates showed no significant trends by race and ethnicity, although Asian donor nonuse rates showed a decrease while the Other category (Native American and Multiracial) increased; these groups are a very small percentage of the overall population (Figure PA 38). Nonuse rates generally increase as the donor BMI increases. For 2023, once BMI was at 30-<35, the nonuse rate climbed to 39.8%, and for BMI of 35-<40, the nonuse rate was greater than 80%; no donors had a BMI of 40 or greater (Figure PA 39). Nonuse rates were not notably different based on disease transmission risk categories, with 22.8% nonuse for donors with risk factors not present and 23.4% nonuse for donors with risk factors present in 2023 (Figure PA 40).

4 Transplants

The overall number of pancreas transplants of all types (SPK, PTA, PAK) was 915 in 2023, reflecting a 12.3% decrease since 2012 (Figure PA 41). There has not been a rebound in any of the type categories following the COVID-19 era, with the most significant decreases in PAK transplants (Figure PA 42). In addition, this was the only category of pancreas transplants that decreased further from the numbers reported in 2022, and has decreased by 70.2% from 121 PAK transplants in 2012 to only 36 in 2023.

The number of pancreas transplants performed in 2023 for recipients younger than 18 years rebounded to 23, from 14 done in 2022 (Figure PA 43). Of interest, the number of pancreas transplants performed at the other end of the age spectrum (55 years and older) also increased, with 124 performed in 2023 compared with 109 in 2022. This was also the only age category that has increased from the number of pancreas transplants performed in 2012. The increase in the number of pancreas recipients aged 55 years or older correlates with the increase in the number of pancreas transplants performed in people with type 2 diabetes. The ratio of pancreas transplants performed in male versus female patients remained relatively unchanged over the past decade, with more male than female recipients (Figure PA 44). The overall number of pancreas transplants in White recipients continued to trend downward, in contrast with other racial and ethnic categories (Figure PA 45). Compared with 2012, the number of pancreas transplants increased in Asian recipients by 370% (47 transplants in 2023 from 10 in 2012), in Black recipients by 58.5% (298 transplants in 2023 from 188 in 2012), and in Hispanic recipients by 42.9% (170 transplants in 2023 from 119 in 2012). The increases in the number of transplants performed in Asian, Black, and Hispanic recipients correlated with the ongoing increases in the number of pancreas transplants being performed for type 2 diabetes (Figure PA 46). The number of pancreas transplants performed in recipients with type 1 diabetes decreased over the past decade by 32% (607 transplants in 2023 from 893 in 2012), whereas the number performed in recipients with type 2 diabetes increased by 236% (232 transplants in 2023 from 69 in 2012).

The use of lymphodepleting induction therapy continued to increase, and 89.0% of adult pancreas transplants performed in 2023 used T-cell–depleting induction only (Figure PA 47). This represents a 14% increase over the past decade. During the same period, the number of pancreas transplants using only interleukin-2 receptor antibodies for induction therapy decreased to 1.5% in 2023, from 8.9% in 2012. Of interest, for 6.8% of pancreas transplants performed in 2023, no induction agent use was reported. Maintenance immunosuppression using tacrolimus and a mycophenolate agent has become the dominant regimen and was used in 95.3% of pancreas transplant recipients in 2023 (Figure PA 48). In 2023, 29.9% of pancreas transplants were maintained on steroid-free regimens, compared with 65.4% on maintenance with triple therapy including tacrolimus, mycophenolate, and steroids. Unsensitized recipients and recipients with calculated panel-reactive antibody of less than 20% constituted 72.2%, 84.8%, and 79.5% of the pancreas transplants for PAK, PTA, and SPK, respectively, in 2023 (Figure PA 49, Figure PA 50, and Figure PA 51). In 2023, most pancreas transplants (41.2%) were performed at centers performing 10 or fewer pancreas transplants, while 26.6% of pancreas transplants were performed at medium-volume centers (11-24 transplants per year) and 32.2% were performed at large-volume centers (25 or more transplants per year) (Figure PA 53).

5 Outcomes

The outcome data in 2023 reflect the fourth year that the Annual Data Report includes the criteria for defining pancreas graft failure if any of the following occurred: 1) a recipient’s transplanted pancreas is removed; 2) a recipient reregisters for a pancreas transplant; 3) a recipient registers for an islet transplant after undergoing a pancreas transplant; 4) a recipient dies; or 5) a recipient’s total insulin use is greater or equal to 0.5 units/kg/day for 90 consecutive days (OPTN Policy 1.2: definitions). The incidence of pancreas graft failure in the first 90 days is generally attributed to technical losses. There was an increase in graft failure in the first 90 days in adults in the PAK category to 16.1% in 2023 (from 6.7% in 2022), whereas the incidence was relatively unchanged following PTA at 9.5% (from 9.4% in 2022) and was lower following SPK at 6.4% (from 7.1% in 2022) (Figure PA 54). Pancreas graft failure within the first year posttransplant has been and remained relatively low since this was first tracked in 2020, and for transplants done in 2022 the 1-year pancreas graft failure rates were 15.6%, 12.5%, and 9.2% following PAK, PTA, and SPK, respectively (Figure PA 55).

The 1-, 5-, and 10-year unadjusted kidney graft failure rates in adults following SPK remained low at 3.8% for transplants performed in 2022, 15.2% for transplants performed in 2018, and 34.4% for transplants performed in 2013, respectively (Figure PA 56). The good long-term kidney function can be attributed, in part, to normalization of hemoglobin A_1C and lack of kidney disease from diabetic nephropathy following successful pancreas transplant. In addition, the high quality of the donor kidneys (low kidney donor profile index) that are used in SPK contributes to the excellent long-term function following SPK. The merits of normalizing hemoglobin A_1C and prevention of diabetic nephropathy are evident with the low 10-year death-censored kidney graft failure rate of 18.7% for SPKs performed in 2013 (Figure PA 57). Similarly, the 10-year death-censored kidney graft failure rate (from the time of pancreas transplant) was 18.5% for pancreas after deceased donor kidney transplants in 2013 and 2014 (Figure PA 59) and 13.7% for pancreas after living donor kidney transplants in 2013 and 2014 (Figure PA 61), which also reflects the beneficial metabolic aspects of successful pancreas transplant in terms of preventing recurrent diabetic nephropathy.

The incidence of acute rejection by 1-year posttransplant for pancreas transplant recipients remains low, and inversely correlates with age. The 1-year rejection rates, reporting only the first reported rejection event, were 10.4%, 8.4%, and 6.4% for recipients aged 18-34 years, 35-49 years, and 50-64 years, respectively (Figure PA 63). The consistency of immunosuppressive regimens following pancreas transplant, with lymphodepletion induction and maintenance including tacrolimus and mycophenolate used in over 90% of pancreas transplants (Figure PA 47 and Figure PA 48), has resulted in the steady reduction of reported rejection rates over the past decade in these age groups (Figure PA 63 and Figure PA 64).

The cumulative incidence of posttransplant lymphoproliferative disorder (PTLD) following pancreas transplant has been a concern based on the more aggressive immunosuppressive regimens that have historically been used to suppress both the alloimmune and autoimmune responses. Despite these concerns, the cumulative incidence of PTLD has remained consistently low, although higher incidence was noted in Epstein-Barr virus (EBV)–negative recipients following pancreas transplant compared with EBV-positive recipients. The 5-year cumulative incidence of PTLD following PAK in adults was 1.1% in EBV-positive compared with 1.6% in EBV-negative recipients (Figure PA 65), and after SPK was 0.7% in EBV-positive and 1.1 % in EBV-negative recipients (Figure PA 67). There was a much higher impact of EBV status in the PTA recipients, with a 5-year cumulative incidence of PTLD of 0.7% in EBV-positive recipients and 4.5% in EBV-negative recipients (Figure PA 66).

The more aggressive immunosuppressive regimens associated with low rejection rates following pancreas transplant have not resulted in higher mortality over the past decade. Although allograft survival was recently defined and allograft success rates are in their fourth year following the new definitions, mortality rates after pancreas transplant have always been accurately monitored by the OPTN. The rates of recipient death at 1 year, 5 years, and 10 years have decreased in every category of pancreas transplant. Mortality at 1 year has decreased from 4.5%, 4.9%, and 4.9% for transplants in 2003 and 2004 to 1.3%, 4.2%, and 2.7% for transplants in 2021 and 2022 following PAK, PTA, and SPK, respectively (Figure PA 68). Mortality at 5 years has decreased from 16.6%, 11.2%, and 13.0% for transplants in 2003 and 2004 to 9.1%, 7.8%, and 9.3% for transplants in 2017 and 2018 following PAK, PTA, and SPK, respectively (Figure PA 69). Longer term mortality at 10 years has decreased from 32.0%, 22.0%, and 26.4% for transplants in 2003 and 2004 to 29.6%, 15.9%, and 21.8% for transplants in 2013 and 2014 following PAK, PTA, and SPK, respectively (Figure PA 70).

Support, Copyright, and Citation Information

This publication was produced for the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), by Hennepin Healthcare Research Institute (HHRI) and the United Network for Organ Sharing (UNOS) under contracts HHSH75R60220C00011 and HHSH250201900001C, respectively. Dr. Israni was supported in part by AHRQ R01HS028829.

This publication lists nonfederal resources in order to provide additional information to consumers. The views and content in these resources have not been formally approved by HHS or HRSA. Neither HHS nor HRSA endorses the products or services of the listed resources.

The OPTN/SRTR 2023 Annual Data Report is not copyrighted. Readers are free to duplicate and use all or part of the information contained in this publication. Data are not copyrighted and may be used without permission if appropriate citation information is provided.

Pursuant to 42 U.S.C. 1320b-10, this publication may not be reproduced, reprinted, or redistributed for a fee without specific written authorization from HHS.

Suggested Citations:

Full citation: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2023 Annual Data Report. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2025. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Abbreviated full citation: OPTN/SRTR 2023 Annual Data Report. HHS/HRSA; 2025. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Chapter citation: [Authors]. OPTN/SRTR 2023 Annual Data Report: [chapter]. Accessed [insert date]. https://srtr.transplant.hrsa.gov/annualdatareports
Chapter citation for AJT e-supplement available at amjtransplant.org: [Authors]. OPTN/SRTR 2023 Annual Data Report: [chapter]. Am J Transplant. 2025;25([issue and suppl numbers]):[page range]. [doi]

Publications based on data in this report or supplied on request must include a citation and the following statement: The data and analyses reported in the OPTN/SRTR 2023 Annual Data Report have been supplied by the United Network for Organ Sharing and Hennepin Healthcare Research Institute under contract with HHS/HRSA. The authors alone are responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the U.S. government.

This report is available at https://srtr.transplant.hrsa.gov/annualdatareports. Individual chapters may be downloaded.

List of Figures

Figure PA 1: New adult candidates added to the pancreas transplant waiting list
Figure PA 2: All adult candidates on the pancreas transplant waiting list
Figure PA 3: Distribution of adults waiting for pancreas transplant by age
Figure PA 4: Distribution of adults waiting for pancreas transplant by sex
Figure PA 5: Distribution of adults waiting for pancreas transplant by race and ethnicity
Figure PA 6: Distribution of adults waiting for pancreas transplant by diagnosis
Figure PA 7: Distribution of adults waiting for pancreas transplant by waiting time
Figure PA 8: Distribution of adults waiting for pancreas transplant by BMI
Figure PA 9: Distribution of adults waiting for pancreas transplant by blood type
Figure PA 10: Distribution of adults waiting for pancreas transplant by intended transplant type
Figure PA 11: Distribution of adults waiting for pancreas transplant by prior transplant status
Figure PA 12: Overall deceased donor pancreas transplant rates among adult waitlist candidates
Figure PA 13: Deceased donor pancreas transplant rates among adult waitlist candidates by diagnosis
Figure PA 14: Deceased donor pancreas transplant rates among adult waitlist candidates by blood type
Figure PA 15: Deceased donor pancreas transplant rates among adult waitlist candidates by intended transplant type
Figure PA 16: Three-year outcomes for adults waiting for pancreas after kidney transplant, new listings in 2018-2020
Figure PA 17: Three-year outcomes for adults waiting for pancreas transplant alone, new listings in 2018-2020
Figure PA 18: Three-year outcomes for adults waiting for simultaneous pancreas-kidney transplant, new listings in 2018-2020
Figure PA 19: Overall pretransplant mortality rates among adults waitlisted for pancreas transplant
Figure PA 20: Pretransplant mortality rates among adults waitlisted for pancreas transplant by age
Figure PA 21: Pretransplant mortality rates among adults waitlisted for pancreas transplant by race and ethnicity
Figure PA 22: Pretransplant mortality rates among adults waitlisted for pancreas transplant by sex
Figure PA 23: Pretransplant mortality rates among adults waitlisted for pancreas transplant by intended transplant type
Figure PA 24: Pretransplant mortality rates among adults waitlisted for pancreas transplant in 2023 by DSA
Figure PA 25: Deaths within 6 months after removal among adult pancreas waitlist candidates, overall
Figure PA 26: Deaths within 6 months after removal among adult pancreas waitlist candidates, by age
Figure PA 27: Deaths within 6 months after removal among adult pancreas waitlist candidates, by intended transplant type
Figure PA 28: Overall deceased pancreas donor count
Figure PA 29: Distribution of deceased pancreas donors by age
Figure PA 30: Distribution of deceased pancreas donors by sex
Figure PA 31: Distribution of deceased pancreas donors by race and ethnicity
Figure PA 32: Distribution of deceased pancreas donors by donor BMI
Figure PA 33: Distribution of deceased pancreas donors by weight
Figure PA 34: Cause of death among deceased pancreas donors
Figure PA 35: Overall rates of pancreata recovered for transplant and not transplanted
Figure PA 36: Rates of pancreata recovered for transplant and not transplanted by donor age
Figure PA 37: Rates of pancreata recovered for transplant and not transplanted by donor sex
Figure PA 38: Rates of pancreata recovered for transplant and not transplanted by donor race and ethnicity
Figure PA 39: Rates of pancreata recovered for transplant and not transplanted by donor BMI
Figure PA 40: Rates of pancreata recovered for transplant and not transplanted, by donor risk of disease transmission
Figure PA 41: Overall pancreas transplants
Figure PA 42: Total pancreas transplants by pancreas transplant type
Figure PA 43: Total pancreas transplants by age
Figure PA 44: Total pancreas transplants by sex
Figure PA 45: Total pancreas transplants by race and ethnicity
Figure PA 46: Total pancreas transplants by diagnosis
Figure PA 47: Induction agent use in adult pancreas transplant recipients
Figure PA 48: Immunosuppression regimen use in adult pancreas transplant recipients
Figure PA 49: CPRA in adult recipients of pancreas after kidney transplant
Figure PA 50: CPRA in adult recipients of pancreas transplant alone
Figure PA 51: CPRA in adult recipients of simultaneous pancreas-kidney transplant
Figure PA 52: Annual adult pancreas transplant center volumes by percentile
Figure PA 53: Distribution of adult pancreas transplants by annual center volume
Figure PA 54: Pancreas graft failure within the first 90 days posttransplant among adult pancreas transplant recipients
Figure PA 55: Pancreas graft failure within the first year posttransplant among adult pancreas transplant recipients
Figure PA 56: Kidney graft failure among adult SPK transplant recipients
Figure PA 57: Death censored kidney graft failure among adult SPK transplant recipients
Figure PA 58: Kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant)
Figure PA 59: Death-censored kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant)
Figure PA 60: Kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant)
Figure PA 61: Death-censored kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant)
Figure PA 62: Recipients alive after pancreas transplant on June 30 of the year, by age at transplant
Figure PA 63: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by age
Figure PA 64: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by induction agent
Figure PA 65: Incidence of PTLD among adult recipients of pancreas after kidney transplant by recipient EBV status at transplant, 2012-2018
Figure PA 66: Incidence of PTLD among adult recipients of pancreas transplant alone by recipient EBV status at transplant, 2012-2018
Figure PA 67: Incidence of PTLD among adult recipients of simultaneous pancreas-kidney transplant by recipient EBV status at transplant, 2012-2018
Figure PA 68: Patient death at 1 year among adult pancreas transplant recipients
Figure PA 69: Patient death at 5 years among adult pancreas transplant recipients
Figure PA 70: Patient death at 10 years among adult pancreas transplant recipients
Figure PA 71: Patient survival among adult deceased donor pancreas transplant recipients, 2016-2018, by transplant type
Figure PA 72: Patient survival among adult deceased donor pancreas transplant recipients, 2016-2018, by diagnosis

List of Tables

Table PA 1: Demographic characteristics of adults on the pancreas transplant waiting list on December 31, 2023
Table PA 2: Clinical characteristics of adults on the pancreas transplant waiting list on December 31, 2023
Table PA 3: Listing characteristics of adults on the pancreas transplant waiting list on December 31, 2023
Table PA 4: Transplant waitlist activity among adults waiting for a pancreas after kidney transplant
Table PA 5: Transplant waitlist activity among adults waiting for a pancreas transplant alone
Table PA 6: Transplant waitlist activity among adults waiting for a simultaneous pancreas-kidney transplant
Table PA 7: Removal reason among adults waiting for pancreas after kidney transplant
Table PA 8: Removal reason among adults waiting for pancreas transplant alone
Table PA 9: Removal reason among adults waiting for simultaneous pancreas-kidney transplant
Table PA 10: Demographic characteristics of adult pancreas transplant recipients, 2023
Table PA 11: Clinical characteristics of adult pancreas transplant recipients, 2023
Table PA 12: Transplant characteristics of adult pancreas transplant recipients, 2023

**New adult candidates added to the pancreas transplant waiting list.** A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and subsequently relisted are considered new.

Figure PA 1: New adult candidates added to the pancreas transplant waiting list. A new candidate is one who first joined the list during the given year, without having been listed in a previous year. Previously listed candidates who underwent transplant and subsequently relisted are considered new.

**All adult candidates on the pancreas transplant waiting list.** Adult candidates on the list at any time during the year. Candidates listed at more than one center are counted once per listing.

Figure PA 2: All adult candidates on the pancreas transplant waiting list. Adult candidates on the list at any time during the year. Candidates listed at more than one center are counted once per listing.

**Distribution of adults waiting for pancreas transplant by age.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year.

Figure PA 3: Distribution of adults waiting for pancreas transplant by age. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive candidates are included. Age is determined at the earliest of transplant, death, removal, or December 31 of the year.

**Distribution of adults waiting for pancreas transplant by sex.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 4: Distribution of adults waiting for pancreas transplant by sex. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adults waiting for pancreas transplant by race and ethnicity.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 5: Distribution of adults waiting for pancreas transplant by race and ethnicity. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adults waiting for pancreas transplant by diagnosis.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 6: Distribution of adults waiting for pancreas transplant by diagnosis. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adults waiting for pancreas transplant by waiting time.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Active and inactive candidates are included.

Figure PA 7: Distribution of adults waiting for pancreas transplant by waiting time. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Time on the waiting list is determined at the earliest of transplant, death, removal, or December 31 of the year. Active and inactive candidates are included.

**Distribution of adults waiting for pancreas transplant by BMI.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. BMI, body mass index.

Figure PA 8: Distribution of adults waiting for pancreas transplant by BMI. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included. BMI, body mass index.

**Distribution of adults waiting for pancreas transplant by blood type.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 9: Distribution of adults waiting for pancreas transplant by blood type. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adults waiting for pancreas transplant by intended transplant type.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 10: Distribution of adults waiting for pancreas transplant by intended transplant type. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Distribution of adults waiting for pancreas transplant by prior transplant status.** Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

Figure PA 11: Distribution of adults waiting for pancreas transplant by prior transplant status. Candidates waiting for transplant at any time in the given year. Candidates listed at more than one center are counted once per listing. Active and inactive patients are included.

**Overall deceased donor pancreas transplant rates among adult waitlist candidates.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 12: Overall deceased donor pancreas transplant rates among adult waitlist candidates. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor pancreas transplant rates among adult waitlist candidates by diagnosis.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 13: Deceased donor pancreas transplant rates among adult waitlist candidates by diagnosis. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor pancreas transplant rates among adult waitlist candidates by blood type.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 14: Deceased donor pancreas transplant rates among adult waitlist candidates by blood type. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Deceased donor pancreas transplant rates among adult waitlist candidates by intended transplant type.** Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

Figure PA 15: Deceased donor pancreas transplant rates among adult waitlist candidates by intended transplant type. Transplant rates are computed as the number of deceased donor transplants per 100 patient-years of waiting time in a given year. Individual listings are counted separately.

**Three-year outcomes for adults waiting for pancreas after kidney transplant, new listings in 2018-2020.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure PA 16: Three-year outcomes for adults waiting for pancreas after kidney transplant, new listings in 2018-2020. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Three-year outcomes for adults waiting for pancreas transplant alone, new listings in 2018-2020.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure PA 17: Three-year outcomes for adults waiting for pancreas transplant alone, new listings in 2018-2020. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Three-year outcomes for adults waiting for simultaneous pancreas-kidney transplant, new listings in 2018-2020.** Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

Figure PA 18: Three-year outcomes for adults waiting for simultaneous pancreas-kidney transplant, new listings in 2018-2020. Candidates listed at more than one center are counted once per listing. Removed from list includes all reasons except transplant and death. DD, deceased donor; LD, living donor.

**Overall pretransplant mortality rates among adults waitlisted for pancreas transplant.** Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure PA 19: Overall pretransplant mortality rates among adults waitlisted for pancreas transplant. Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adults waitlisted for pancreas transplant by age.** Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

Figure PA 20: Pretransplant mortality rates among adults waitlisted for pancreas transplant by age. Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. Age is determined at the later of listing date or January 1 of the given year.

**Pretransplant mortality rates among adults waitlisted for pancreas transplant by race and ethnicity.** Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American and Multiracial categories.

Figure PA 21: Pretransplant mortality rates among adults waitlisted for pancreas transplant by race and ethnicity. Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. The Other race category is composed of Native American and Multiracial categories.

**Pretransplant mortality rates among adults waitlisted for pancreas transplant by sex.** Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure PA 22: Pretransplant mortality rates among adults waitlisted for pancreas transplant by sex. Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adults waitlisted for pancreas transplant by intended transplant type.** Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

Figure PA 23: Pretransplant mortality rates among adults waitlisted for pancreas transplant by intended transplant type. Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately.

**Pretransplant mortality rates among adults waitlisted for pancreas transplant in 2023 by DSA.** Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. DSA, donation service area.

Figure PA 24: Pretransplant mortality rates among adults waitlisted for pancreas transplant in 2023 by DSA. Mortality rates are computed as the number of deaths per 100 patient-years of waiting time in the given year. Waiting time is censored at transplant, death, transfer to another program, removal because of improved condition, or end of cohort. Individual listings are counted separately. DSA, donation service area.

**Deaths within 6 months after removal among adult pancreas waitlist candidates, overall.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure PA 25: Deaths within 6 months after removal among adult pancreas waitlist candidates, overall. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

**Deaths within 6 months after removal among adult pancreas waitlist candidates, by age.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list. Age is determined at removal.

Figure PA 26: Deaths within 6 months after removal among adult pancreas waitlist candidates, by age. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list. Age is determined at removal.

**Deaths within 6 months after removal among adult pancreas waitlist candidates, by intended transplant type.** Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

Figure PA 27: Deaths within 6 months after removal among adult pancreas waitlist candidates, by intended transplant type. Denominator includes only candidates removed from the waiting list for reasons other than transplant or death while on the list.

**Overall deceased pancreas donor count.** Count of deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 28: Overall deceased pancreas donor count. Count of deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Distribution of deceased pancreas donors by age.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 29: Distribution of deceased pancreas donors by age. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Distribution of deceased pancreas donors by sex.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 30: Distribution of deceased pancreas donors by sex. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Distribution of deceased pancreas donors by race and ethnicity.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American and Multiracial categories.

Figure PA 31: Distribution of deceased pancreas donors by race and ethnicity. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American and Multiracial categories.

**Distribution of deceased pancreas donors by donor BMI.** Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. BMI, body mass index.

Figure PA 32: Distribution of deceased pancreas donors by donor BMI. Deceased donors whose pancreata were recovered for transplant. Pancreata recovered for islet transplant are excluded. BMI, body mass index.

Figure PA 33: Distribution of deceased pancreas donors by weight. Deceased donors whose pancreata were recovered for transplant.

**Cause of death among deceased pancreas donors.** Donors whose pancreata were recovered for transplant. CVA, cerebrovascular accident.

Figure PA 34: Cause of death among deceased pancreas donors. Donors whose pancreata were recovered for transplant. CVA, cerebrovascular accident.

**Overall rates of pancreata recovered for transplant and not transplanted.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 35: Overall rates of pancreata recovered for transplant and not transplanted. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Rates of pancreata recovered for transplant and not transplanted by donor age.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the age category in the year.

Figure PA 36: Rates of pancreata recovered for transplant and not transplanted by donor age. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the age category in the year.

**Rates of pancreata recovered for transplant and not transplanted by donor sex.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

Figure PA 37: Rates of pancreata recovered for transplant and not transplanted by donor sex. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded.

**Rates of pancreata recovered for transplant and not transplanted by donor race and ethnicity.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American and Multiracial categories.

Figure PA 38: Rates of pancreata recovered for transplant and not transplanted by donor race and ethnicity. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. The Other race category is composed of Native American and Multiracial categories.

**Rates of pancreata recovered for transplant and not transplanted by donor BMI.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the BMI category in the year. BMI, body mass index.

Figure PA 39: Rates of pancreata recovered for transplant and not transplanted by donor BMI. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. Missing dots indicate no pancreata were recovered from donors in the BMI category in the year. BMI, body mass index.

**Rates of pancreata recovered for transplant and not transplanted, by donor risk of disease transmission.** Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. "Risk factors" refers to risk criteria for acute transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus from the US Public Health Service Guideline.

Figure PA 40: Rates of pancreata recovered for transplant and not transplanted, by donor risk of disease transmission. Percentages of pancreata not transplanted out of all pancreata recovered for transplant. Pancreata recovered for islet transplant are excluded. “Risk factors” refers to risk criteria for acute transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus from the US Public Health Service Guideline.

**Overall pancreas transplants.** All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

Figure PA 41: Overall pancreas transplants. All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

**Total pancreas transplants by pancreas transplant type.** All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

Figure PA 42: Total pancreas transplants by pancreas transplant type. All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

**Total pancreas transplants by age.** All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

Figure PA 43: Total pancreas transplants by age. All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

**Total pancreas transplants by sex.** All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

Figure PA 44: Total pancreas transplants by sex. All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

**Total pancreas transplants by race and ethnicity.** All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

Figure PA 45: Total pancreas transplants by race and ethnicity. All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

**Total pancreas transplants by diagnosis.** All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

Figure PA 46: Total pancreas transplants by diagnosis. All pancreas transplant recipients, including adult and pediatric, retransplant, and multiorgan recipients.

**Induction agent use in adult pancreas transplant recipients.** Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure PA 47: Induction agent use in adult pancreas transplant recipients. Immunosuppression at transplant reported to the OPTN. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Immunosuppression regimen use in adult pancreas transplant recipients.** Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

Figure PA 48: Immunosuppression regimen use in adult pancreas transplant recipients. Immunosuppression regimen at transplant reported to the OPTN. MMF, all mycophenolate agents; Tac, tacrolimus.

**CPRA in adult recipients of pancreas after kidney transplant.** Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 49: CPRA in adult recipients of pancreas after kidney transplant. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**CPRA in adult recipients of pancreas transplant alone.** Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 50: CPRA in adult recipients of pancreas transplant alone. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

**CPRA in adult recipients of simultaneous pancreas-kidney transplant.** Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 51: CPRA in adult recipients of simultaneous pancreas-kidney transplant. Peak cPRA is used. Missing indicates no unacceptable antigens were reported. cPRA, calculated panel-reactive antibody.

Figure PA 52: Annual adult pancreas transplant center volumes by percentile. Annual volume data are limited to recipients aged 18 years or older.

**Distribution of adult pancreas transplants by annual center volume.** Based on annual volume data among recipients aged 18 years or older.

Figure PA 53: Distribution of adult pancreas transplants by annual center volume. Based on annual volume data among recipients aged 18 years or older.

**Pancreas graft failure within the first 90 days posttransplant among adult pancreas transplant recipients.** All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Transplants after September 30, 2023, are excluded due to insufficient follow-up. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 54: Pancreas graft failure within the first 90 days posttransplant among adult pancreas transplant recipients. All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Transplants after September 30, 2023, are excluded due to insufficient follow-up. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Pancreas graft failure within the first year posttransplant among adult pancreas transplant recipients.** All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 55: Pancreas graft failure within the first year posttransplant among adult pancreas transplant recipients. All-cause graft failure is identified from multiple data sources, including the OPTN Transplant Recipient Registration Form, the OPTN Transplant Recipient Follow-up Form, and death dates from the Social Security Administration. Nonrenal multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Kidney graft failure among adult SPK transplant recipients.** Estimates are unadjusted, computed using Kaplan-Meier methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

Figure PA 56: Kidney graft failure among adult SPK transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

**Death censored kidney graft failure among adult SPK transplant recipients.** Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

Figure PA 57: Death censored kidney graft failure among adult SPK transplant recipients. Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. SPK transplant recipients are followed from date of transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. Nonrenal multivisceral transplants are excluded. SPK, simultaneous pancreas-kidney.

**Kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 58: Kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

**Death-censored kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 59: Death-censored kidney graft failure among adult PAK transplant recipients with a deceased donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent deceased donor kidney transplant are followed from the date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of previous kidney or kidney-pancreas transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

**Kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 60: Kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. All-cause graft failure is defined as any of the above outcomes prior to 1, 5, or 10 years, respectively. All time points are 2-year periods. PAK, pancreas after kidney.

**Death-censored kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant).** Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

Figure PA 61: Death-censored kidney graft failure among adult PAK transplant recipients with a living donor kidney (from time of pancreas transplant). Estimates are unadjusted, computed using Kaplan-Meier competing risk methods. PAK transplant recipients who previously underwent living donor kidney transplant are followed from date of pancreas transplant to the earliest of kidney graft failure; kidney retransplant; return to dialysis; death; or 1, 5, or 10 years posttransplant. Only PAK recipients with an OPTN record of a previous living kidney donor transplant are included. Multivisceral transplants are excluded. Death-censored graft failure is defined as return to dialysis, reported graft failure, or kidney retransplant. All time points are 2-year periods. PAK, pancreas after kidney.

**Recipients alive after pancreas transplant on June 30 of the year, by age at transplant.** Recipients are not censored at reported graft failure since the uniform definition of graft failure was not in effect until 2018. However, a recipient may experience a reported graft failure and be removed from the cohort, undergo retransplant, and re-enter the cohort.

Figure PA 62: Recipients alive after pancreas transplant on June 30 of the year, by age at transplant. Recipients are not censored at reported graft failure since the uniform definition of graft failure was not in effect until 2018. However, a recipient may experience a reported graft failure and be removed from the cohort, undergo retransplant, and re-enter the cohort.

**Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by age.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Missing dots indicate no pancreata were transplanted in patients in the age category in the year.

Figure PA 63: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by age. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. Missing dots indicate no pancreata were transplanted in patients in the age category in the year.

**Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by induction agent.** Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

Figure PA 64: Incidence of acute rejection by 1 year posttransplant among adult pancreas transplant recipients by induction agent. Only the first reported rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier method. IL2Ab, interleukin-2 receptor antibody; TCD, T-cell depleting.

**Incidence of PTLD among adult recipients of pancreas after kidney transplant by recipient EBV status at transplant, 2012-2018.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure PA 65: Incidence of PTLD among adult recipients of pancreas after kidney transplant by recipient EBV status at transplant, 2012-2018. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

**Incidence of PTLD among adult recipients of pancreas transplant alone by recipient EBV status at transplant, 2012-2018.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure PA 66: Incidence of PTLD among adult recipients of pancreas transplant alone by recipient EBV status at transplant, 2012-2018. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

**Incidence of PTLD among adult recipients of simultaneous pancreas-kidney transplant by recipient EBV status at transplant, 2012-2018.** Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin's disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

Figure PA 67: Incidence of PTLD among adult recipients of simultaneous pancreas-kidney transplant by recipient EBV status at transplant, 2012-2018. Cumulative incidence is estimated using the Kaplan-Meier method. PTLD is identified as a reported complication or cause of death on the OPTN Transplant Recipient Follow-up Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.

**Patient death at 1 year among adult pancreas transplant recipients.** Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 1 year posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 68: Patient death at 1 year among adult pancreas transplant recipients. Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 1 year posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Patient death at 5 years among adult pancreas transplant recipients.** Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 5 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 69: Patient death at 5 years among adult pancreas transplant recipients. Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 5 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Patient death at 10 years among adult pancreas transplant recipients.** Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 10 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 70: Patient death at 10 years among adult pancreas transplant recipients. Outcomes are computed using unadjusted Kaplan-Meier methods. Transplant recipients are followed from date of transplant to the earlier of death or 10 years posttransplant. Only first pancreas transplant is considered. PAK recipients without a record of previous kidney or kidney-pancreas transplant are reclassified as PTA. All time points are 2-year periods. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Patient survival among adult deceased donor pancreas transplant recipients, 2016-2018, by transplant type.** Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

Figure PA 71: Patient survival among adult deceased donor pancreas transplant recipients, 2016-2018, by transplant type. Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.

**Patient survival among adult deceased donor pancreas transplant recipients, 2016-2018, by diagnosis.** Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded.

Figure PA 72: Patient survival among adult deceased donor pancreas transplant recipients, 2016-2018, by diagnosis. Patient survival estimated using unadjusted Kaplan-Meier methods. Multivisceral transplants are excluded.

Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Age (years)
18-34 years	22	8.4	92	24.6	444	21.6	558	20.8
35-44	94	36.0	118	31.6	755	36.8	967	36.0
45-54	98	37.5	114	30.5	578	28.2	790	29.4
55+	47	18.0	50	13.4	275	13.4	372	13.8
Sex
Female	118	45.2	199	53.2	957	46.6	1,274	47.4
Male	143	54.8	175	46.8	1,095	53.4	1,413	52.6
Race and ethnicity
Asian	11	4.2	10	2.7	115	5.6	136	5.1
Black	63	24.1	63	16.8	624	30.4	750	27.9
Hispanic	51	19.5	50	13.4	366	17.8	467	17.4
Multiracial	1	0.4	2	0.5	27	1.3	30	1.1
Native American	4	1.5	2	0.5	24	1.2	30	1.1
White	131	50.2	246	65.8	894	43.6	1,271	47.3
Unreported	0	0	1	0.3	2	0.1	3	0.1
Body mass index
<18.5	4	1.5	17	4.5	30	1.5	51	1.9
18.5-<25	86	33.0	137	36.6	668	32.6	891	33.2
25-<30	100	38.3	141	37.7	853	41.6	1,094	40.7
30-<35	57	21.8	62	16.6	410	20.0	529	19.7
35+	14	5.4	17	4.5	91	4.4	122	4.5
Miles between candidate and center
<50 miles	166	63.6	198	52.9	1,263	61.5	1,627	60.6
50-<100	46	17.6	48	12.8	359	17.5	453	16.9
100-<150	21	8.0	27	7.2	170	8.3	218	8.1
150-<250	13	5.0	33	8.8	145	7.1	191	7.1
250+	14	5.4	65	17.4	94	4.6	173	6.4
Missing	1	0.4	3	0.8	21	1.0	25	0.9
All candidates
All candidates	261	100.0	374	100.0	2,052	100.0	2,687	100.0
OPTN/SRTR 2023 Annual Data Report

Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Diagnosis
Diabetes type 1	186	71.3	269	71.9	1,379	67.2	1,834	68.3
Diabetes type 2	65	24.9	29	7.8	539	26.3	633	23.6
Other/unknown	10	3.8	76	20.3	134	6.5	220	8.2
Blood type
A	88	33.7	144	38.5	605	29.5	837	31.1
AB	16	6.1	14	3.7	55	2.7	85	3.2
B	37	14.2	52	13.9	382	18.6	471	17.5
O	120	46.0	164	43.9	1,010	49.2	1,294	48.2
All candidates
All candidates	261	100.0	374	100.0	2,052	100.0	2,687	100.0
OPTN/SRTR 2023 Annual Data Report

Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Waiting time
<90 days	24	9.2	44	11.8	311	15.2	379	14.1
3-<6 months	35	13.4	45	12.0	300	14.6	380	14.1
6-<12 months	33	12.6	57	15.2	438	21.3	528	19.7
1-<2 years	35	13.4	79	21.1	492	24.0	606	22.6
2+ years	134	51.3	149	39.8	511	24.9	794	29.5
Previous transplant
No prior transplant	203	77.8	338	90.4	1,963	95.7	2,504	93.2
Prior transplant	58	22.2	36	9.6	89	4.3	183	6.8
All candidates
All candidates	261	100.0	374	100.0	2,052	100.0	2,687	100.0
OPTN/SRTR 2023 Annual Data Report

Waiting list state	2021	2022	2023
Waiting list state
Patients at start of year	293	284	259
Patients added during year	106	71	111
Patients removed during year	115	96	109
Patients at end of year	284	259	261
OPTN/SRTR 2023 Annual Data Report

Waiting list state	2021	2022	2023
Waiting list state
Patients at start of year	362	361	384
Patients added during year	181	180	180
Patients removed during year	182	157	190
Patients at end of year	361	384	374
OPTN/SRTR 2023 Annual Data Report

Removal reason	2021	2022	2023
Removal reason
Deceased donor transplant	34	29	25
Patient died	6	3	8
Patient refused transplant	4	3	7
Improved, transplant not needed	2	1	1
Too sick for transplant	11	16	14
Other	54	44	52
Changed to kidney-pancreas list	3	0	2
Still on waiting list	1	0	0
OPTN/SRTR 2023 Annual Data Report

**Table PA 10:** **Demographic characteristics of adult pancreas transplant recipients, 2023.** Pancreas transplant recipients, including retransplant recipients. Distance is computed from recipient's home zip code to the transplant center. PAK, pancreas after kidney; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney.
Characteristic	PAK N	PAK Percent	PTA N	PTA Percent	SPK N	SPK Percent	All N	All Percent
Recipient age (years)
18-34 years	6	16.7	11	23.9	178	22.0	195	21.9
35-49	21	58.3	15	32.6	422	52.1	458	51.3
50-64	9	25.0	19	41.3	203	25.1	231	25.9
65+	0	0	1	2.2	7	0.9	8	0.9
Sex
Female	16	44.4	25	54.3	331	40.9	372	41.7
Male	20	55.6	21	45.7	479	59.1	520	58.3
Race and ethnicity
Asian	2	5.6	2	4.3	40	4.9	44	4.9
Black	8	22.2	3	6.5	282	34.8	293	32.8
Hispanic	1	2.8	3	6.5	162	20.0	166	18.6
Multiracial	1	2.8	0	0	5	0.6	6	0.7
Native American	0	0	0	0	5	0.6	5	0.6
White	24	66.7	38	82.6	316	39.0	378	42.4
Body mass index
<18.5	0	0	4	8.7	18	2.2	22	2.5
18.5-<25	15	41.7	19	41.3	326	40.2	360	40.4
25-<30	13	36.1	19	41.3	320	39.5	352	39.5
30-<35	7	19.4	4	8.7	121	14.9	132	14.8
35+	0	0	0	0	13	1.6	13	1.5
Missing	1	2.8	0	0	12	1.5	13	1.5
Insurance
Private	15	41.7	37	80.4	299	36.9	351	39.3
Medicare	15	41.7	4	8.7	382	47.2	401	45.0
Medicaid	4	11.1	4	8.7	108	13.3	116	13.0
Other/unknown	2	5.6	1	2.2	21	2.6	24	2.7
Miles between recipient and center
<50 miles	20	55.6	20	43.5	490	60.5	530	59.4
50-<100	5	13.9	6	13.0	144	17.8	155	17.4
100-<150	7	19.4	4	8.7	75	9.3	86	9.6
150-<250	1	2.8	5	10.9	46	5.7	52	5.8
250+	1	2.8	10	21.7	39	4.8	50	5.6
Missing	2	5.6	1	2.2	16	2.0	19	2.1
All recipients
All recipients	36	100.0	46	100.0	810	100.0	892	100.0
OPTN/SRTR 2023 Annual Data Report

OPTN/SRTR 2023 Annual Data Report: Pancreas

Raja Kandaswamy1,2, Peter G. Stock1,3, Jonathan M. Miller1,4, Dzhuliyana Handarova5, Ajay K. Israni1,6, Jon J. Snyder1,4,7

1Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN

2Department of Surgery, University of Minnesota, Minneapolis, MN

3Department of Surgery, University of California San Francisco, San Francisco, CA

4Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, MN

5Organ Procurement and Transplantation Network, United Network for Organ Sharing, Richmond, VA

6Department of Medicine, University of Texas Medical Branch, Galveston, TX

7Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN